US23282W6057 - Common Stock - After market: 40.97 -0.03 (-0.07%)
NASDAQ:CYTK (7/1/2022, 7:08:09 PM)+1.71 (+4.35%)
|GICS Sector||Health Care|
|Earnings (Last)||05-04 2022-05-04/amc||Earnings (Next)||08-03 2022-08-03|
|Ins Owners||1.29%||Inst Owners||111.57%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Cytokinetics, Inc. operates as a biopharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 253 full-time employees. The company went IPO on 2004-04-29. The company is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates are: omecamtiv mecarbil, a cardiac myosin activator for the treatment of heart failure with reduced ejection fraction (HFrEF); CK-136, a cardiac troponin activator for the treatment of heart failure and other diseases; reldesemtiv (CK-2127107), a fast skeletal muscle troponin activator (FSTA) for the treatment of people living with debilitating diseases and conditions associated with muscular weakness; aficamten (CK-274), a cardiac myosin inhibitor designed to reduce the hypercontractility that is associated with hypertrophic cardiomyopathy (HCM); and CK-3772271 (CK-271), a second novel cardiac myosin inhibitor.
., 280 East Grand Avenue
South San Francisco CALIFORNIA 94080
CEO: Robert I. Blum
SOUTH SAN FRANCISCO, Calif., July 01, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of...
The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today.
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced its intention...
Here you can normally see the latest stock twits on CYTK, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.